Carol Gallagher biography
Dr. Carol G. Gallagher serves as Independent Director of the Company. She is currently the independent lead director at Atara Bio and Chairperson of Millendo Therapeutics, both public biopharmaceutical companies. Since 2014, Dr. Gallagher has served as a partner with New Enterprise Associates, a venture capital firm. She also currently serves as a director on several private, healthcare company boards. From 2011 until 2018, she was a director at AnaptysBio and she also served as a director of several private boards prior to joining New Enterprise Associates. Dr. Gallagher served as a venture partner with Frazier Healthcare from October 2013 to July 2014. Dr. Gallagher served as President and CEO of Calistoga Pharmaceuticals from September 2008 until April 2011 when the company was acquired by Gilead Sciences. From 2007 to 2008, Dr. Gallagher served as president and CEO of Metastatix, Inc, a biopharmaceutical company. Prior to that time, starting in 1989, she served in various roles at pharmaceutical companies Eli Lilly, Amgen, Agouron Pharmaceuticals, Pfizer, Biogen Idec, CancerVax and Anadys Pharmaceuticals. She studied chemistry at Vanderbilt University and attained her B.S. and Doctor of Pharmacy degrees from the University of Kentucky.
What is the salary of Carol Gallagher?
As the Independent Director of Turning Point Therapeutics Inc, the total compensation of Carol Gallagher at Turning Point Therapeutics Inc is $839,556. There are 5 executives at Turning Point Therapeutics Inc getting paid more, with Yi Larson having the highest compensation of $12,579,400.
